首页HXB • FRA
add
AIM ImmunoTech Inc
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2025年12月info | 年同比变化 |
|---|---|---|
收入 | 2.10万 | -53.33% |
经营支出 | 293.30万 | -50.23% |
净收入 | -417.50万 | 30.03% |
净利润率 | -1.99万 | -49.93% |
每股收益 | -0.44 | 95.60% |
息税折旧摊销前利润 | -290.90万 | 49.77% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2025年12月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 304.70万 | -23.38% |
总资产 | 578.20万 | -32.83% |
负债总额 | 1556.50万 | 56.75% |
权益总额 | -978.30万 | — |
发行在外的股份 | 814.78万 | — |
市净率 | -1.91 | — |
资产回报率 | -130.90% | — |
资本回报率 | 171.11% | — |
现金流
现金净变动
| (USD) | 2025年12月info | 年同比变化 |
|---|---|---|
净收入 | -417.50万 | 30.03% |
来自运营的现金 | -198.60万 | 49.79% |
投资现金 | -9.50万 | -102.56% |
融资现金 | 271.90万 | 162.20% |
现金净变动 | 63.80万 | -18.83% |
自由现金流 | -142.94万 | 74.40% |
简介
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
成立时间
1966
员工数量
20
